A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.
about
Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trialsBiomarkers in phase I-II chemoprevention trials: lessons from the NCI experienceA multi-targeted approach to suppress tumor-promoting inflammationSulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidenceGenistein induces deleterious effects during its acute exposure in Swiss mice.Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B InhibitorPredictors of willingness to participate in window-of-opportunity breast trialsGenistein: the potential for efficacy in rheumatoid arthritis.Effects of deranged metabolism on epigenetic changes in cancer.Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.Epigenetic targets in cancer and aging: dietary and therapeutic interventions.The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis.Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.Impact of Phytochemicals and Dietary Patterns on Epigenome and Cancer.Natural Products for the Management and Prevention of Breast Cancer.A Festschrift in Honor of Edward M. Messing, MD, FACS
P2860
Q26765196-8B53A0FF-2EF2-4CBE-BEF1-284ED8308A96Q26774585-66DD2C9E-8240-4431-98CC-9BBBE2DDC8AAQ28393278-6F5DB34E-029F-4B5D-A1BA-C9C918894308Q30234740-1BB17E34-B085-4AB7-ADA8-651397E6B238Q30845020-6E04AB5C-4BF8-43F7-8575-809E4CE133A1Q33746145-BB83E7D7-229A-4284-A4D1-2836508AEEA2Q34663992-58C73205-E180-4702-A855-DC313CD777E8Q36784782-E7CF6178-793B-41AD-BAA1-8AEA9A7E8225Q37210705-C4133586-E895-4DA6-860B-2C5ED50FA96EQ38073177-2E1BEEAC-8F8E-4E74-9C3F-6BFC12231029Q38335029-E351E1A3-7614-4A48-B9C2-73B091D167BCQ38512046-AF3E59B9-4989-404F-8846-29874929A54FQ38669233-A675C02B-027F-476E-A152-340EC78AA52DQ38703610-FFCF1CF7-07EE-44DA-9192-E3EADD88DAA2Q38931011-00CEB30F-70AF-4823-9D56-4FDD6B833263Q50083416-71DF239B-DEA9-43AD-AC9D-24E646FBC773Q51187064-A567DDCB-FA59-40ED-ABEC-00122D313296Q55043805-FC8376B0-439C-4CCF-BDA1-C06DCD993386Q58691149-060D7118-5B8B-46F6-ACC5-FB2E4F50109D
P2860
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@ast
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@en
type
label
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@ast
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@en
prefLabel
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@ast
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@en
P2093
P2860
P1476
A phase 2 cancer chemopreventi ...... gical bladder cancer patients.
@en
P2093
Adrienne Faerber
Anthony diSant'Agnese
Daniel R Saltzstein
Edward Messing
Howard Bailey
Howard Parnes
J Erik Busby
Jason R Gee
Jay M Young
Jill Kolesar
P2860
P304
P356
10.1158/1940-6207.CAPR-11-0455
P577
2012-01-31T00:00:00Z